Shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) have earned a consensus recommendation of "Reduce" from the six research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $24.40.
Several analysts have recently commented on PAHC shares. BNP Paribas raised Phibro Animal Health to a "hold" rating in a research note on Monday, June 16th. Morgan Stanley set a $26.00 price objective on Phibro Animal Health and gave the company an "equal weight" rating in a research note on Wednesday, June 25th. Wall Street Zen raised shares of Phibro Animal Health from a "hold" rating to a "buy" rating in a report on Friday, May 9th. BNP Paribas Exane raised shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price objective on the stock in a report on Monday, June 16th. Finally, JPMorgan Chase & Co. raised shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and lifted their price objective for the stock from $25.00 to $35.00 in a report on Monday, July 7th.
Check Out Our Latest Stock Report on PAHC
Hedge Funds Weigh In On Phibro Animal Health
Several institutional investors have recently bought and sold shares of PAHC. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Phibro Animal Health in the fourth quarter worth $29,000. National Bank of Canada FI bought a new position in shares of Phibro Animal Health during the first quarter valued at about $30,000. Lazard Asset Management LLC grew its stake in shares of Phibro Animal Health by 2,739.7% during the fourth quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock valued at $34,000 after buying an additional 1,589 shares during the last quarter. Aquatic Capital Management LLC bought a new position in shares of Phibro Animal Health during the fourth quarter valued at about $69,000. Finally, Virtus Fund Advisers LLC bought a new position in shares of Phibro Animal Health during the fourth quarter valued at about $69,000. Hedge funds and other institutional investors own 99.34% of the company's stock.
Phibro Animal Health Stock Up 2.4%
Phibro Animal Health stock traded up $0.74 during midday trading on Friday, reaching $31.54. The stock had a trading volume of 327,172 shares, compared to its average volume of 221,559. Phibro Animal Health has a 12 month low of $16.16 and a 12 month high of $31.80. The company has a market capitalization of $1.28 billion, a P/E ratio of 40.44, a PEG ratio of 0.52 and a beta of 0.75. The company has a fifty day moving average price of $24.79 and a two-hundred day moving average price of $22.45. The company has a current ratio of 2.91, a quick ratio of 1.23 and a debt-to-equity ratio of 2.67.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.52 by $0.11. Phibro Animal Health had a return on equity of 30.51% and a net margin of 2.68%. The business had revenue of $347.80 million during the quarter, compared to analyst estimates of $352.41 million. As a group, equities analysts expect that Phibro Animal Health will post 1.95 EPS for the current fiscal year.
Phibro Animal Health Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Wednesday, June 4th were issued a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.52%. The ex-dividend date was Wednesday, June 4th. Phibro Animal Health's dividend payout ratio is presently 61.54%.
About Phibro Animal Health
(
Get Free ReportPhibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Recommended Stories
Before you consider Phibro Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.
While Phibro Animal Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
